Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021
Catalyst Supporting Facebook Live Panelon Living with a Rare Disease Hosted by The Mighty
- Catalyst Kicks off Rare Reason Campaign
Rare Disease Day, observed on
As a public demonstration of support, members of Catalyst’s team will be joining the
Dedicated to raising awareness of rare disease and its challenges; Catalyst is sponsoring and will participate in a
"Rare disease day is a great opportunity to drive awareness around the rare diseases that 300 million people live with," said
|Details of the Facebook Live event
|Panelist:||Chip, a LEMS patient ambassador|
|Subject:||Late-onset diagnosis of rare disease, misdiagnosis, and living with a chronic illness from a patient and HCP perspective|
“With over 300 million members, we are proud to support the effort to build unity within the rare and ultra-rare disease community," said
For information about Rare Disease Day activities, visit https://rarediseases.org/rare-disease-day/.
Firdapse is currently being evaluated in clinical trials for the treatment of MuSK-MG and has received Orphan Drug Designation from the FDA for myasthenia gravis.
About The Mighty
The Mighty is the world’s leading health community, revolutionizing the way people think and talk about health. With more than 3 million members and billions of views on the health stories their members share, The Mighty provides its members with connection and support and provides its partners with insights and marketing opportunities across thousands of health conditions, including many rare diseases.
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2019 and its other filings with the
|(646) 378-2923||Chief Executive Officer|
Source: Catalyst Pharmaceuticals, Inc.